Tissue Chip Funding Information

NIH launched the Tissue Chip for Drug Screening program to develop 3-D human tissue chips containing bioengineered models that mimic human physiology. The aim is to use these chips to better predict the safety and effectiveness of candidate drugs. Scientists now are collaborating to combine the chips into an integrated system or human body-on-a-chip.

Current Opportunities

  • PAR-19-138: ImmuneChip: Engineering Microphysiological Immune Tissue Platforms (U01 Clinical Trial Not Allowed)
  • PA-18-591: Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)​
    • NOT-TR-19-009: Notice of Correction to Revise Application Due Dates for NOT-TR-19-001 Notice of Availability of Administrative Supplements for Microphysiological Systems Developers: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
    • NOT-TR-18-027: Notice of Availability of Administrative Supplements for Tissue Chip Consortium Awardees: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
    • NOT-TR-19-001: Notice of Availability of Administrative Supplements for Microphysiological Systems Developers : Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
  • NOT-TR-19-007: Notice of Intent to Publish a Funding Opportunity Announcement for Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)

Expired Announcements

These expired funding announcements include details on the application process, eligibility and timelines for the program:

  • RFA-TR-19-003: HEAL Initiative: Tissue Chips to Model Nociception, Addiction, and Overdose (UG3/UH3 Clinical Trial Not Allowed)
  • RFA-TR-18-006: NextGen Tissue Chip Testing Centers: Validating Microphysiological Systems (U24 Clinical Trial Not Allowed)
  • RFA-TR-18-005: Microphysiological Systems Data Center U24 (Clinical Trial Not Allowed)
  • RFA-TR-18-001: NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3 Clinical Trials Not Allowed)
    • NOT-TR-18-014: Notice of Change to Receipt Date on NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3 Clinical Trials Not Allowed) (RFA-TR-18-001)
  • RFA-DK-17-035: Microphysiological Systems for Modeling Diabetes (UG3/UH3 - Clinical Trial Not Allowed)
  • RFA-TR-16-017: Microphysiological Systems (MPS) for Disease Modeling and Efficacy Testing (UG3/UH3)
    • NOT-TR-18-027: Notice of Availability of Administrative Supplements for Tissue Chip Consortium Awardees: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
  • RFA-TR-16-019: NIH-CASIS Coordinated Microphysiological Systems Program for Translational Research in Space (UG3/UH3)
    • NOT-TR-18-027: Notice of Availability of Administrative Supplements for Tissue Chip Consortium Awardees: Development of Tissue Chips to Model Nociception, Opioid Addiction and Overdose
  • PA-16-178: Limited Competition: Tissue Chips and Missing Organs (Admin Supp)
  • PA-16-173: Limited Competition: Tissue Chips for Rare Diseases (Admin Supp)
  • RFA-TR-16-006: Tissue Chip Testing Centers: Validating Microphysiological Systems (U24)
  • RFA-RM-11-022: Integrated Microphysiological Systems for Drug Efficacy and Toxicity Testing in Human Health and Disease (UH2/UH3)
  • RFA-RM-12-001: Stem/Progenitor Cell-Derived Human Micro-Organs and -Tissues (U18)

NCATS acknowledges the following NIH Institutes for their contribution to this trans-NIH program: the Eunice Kennedy Shriver National Institute of Child Health and Human Development; the National Cancer Institute; the National Eye Institute; the National Heart, Lung, and Blood Institute; the National Institute of Allergy and Infectious Diseases; the National Institute of Arthritis and Musculoskeletal and Skin Diseases; the National Institute of Biomedical Imaging and Bioengineering; the National Institute of Dental and Craniofacial Research; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute of Environmental Health Sciences; the National Institute of General Medical Sciences; the National Institute of Neurological Disorders and Stroke; the National Institute of Nursing Research; and the National Institute on Drug Abuse. NIH’s Common Fund and National Institute of Neurological Disorders and Stroke initially led trans-NIH efforts to establish the program.